文献库搜索 | GeneLibs

Holm(KY),Mohammed(Y),Gunnarsdottir Thormar... Breast Cancer Res 2026-07-18

...BRCA2 mutation carriers (n = 7) diagnosed with breast cancer within 5 years of blood collection than among paired contro...

Zou(Z),Lu(G),Xin(M),Du(Z),Cheng(Z),Wu(S),C... J Med Chem 2026-08-13

...BRCA2-deficient cell line (Capan-1). Mechanistic studies revealed that 24c effectively inhibited intracellular PARP-1 ac...

Chen(MY),Zhou(JL),Zhang(XY),Zhai(QZ),Li(MX... Zhonghua Zhong Liu Za Zhi 2026-07-23

...BRCA2 mutation group (29 cases). The clinical baseline data, pathological characteristics, treatment efficacy, and survi...

Li(NM),Cheng(HP),Zhou(P),Li(XH) Zhonghua Zhong Liu Za Zhi 2026-07-23

...BRCA2 mutation and was HRD score-positive. TMB-H status was significantly associated with HRD positivity (P＜0.05), where...

Tooming(M),Rekker(K),Toome(K),Roht(L),Laid... Front Genet None

...BRCA2, and other cancer-associated genes plays a critical role in the diagnosis, prognosis, and management of breast and...

Cruellas(M),Rodriguez-Hernandez(A),Carità(... ESMO Open 2026-08-00

...BRCA2 tumors. BRCA2 PVs were independently associated with poorer outcomes to first-line CDK4/6i plus ET in HR-positive/...

Saylor(KW),Rasmussen(SA),Murray(MF) NEJM Evid 2026-02-00

...BRCA2-associated cancer risk, where current risk-identification strategies have been shown to miss greater than 70% of a...

Ferrandi(G),Bagnolini(G),Poppi(L),Masi(M),... ACS Med Chem Lett 2026-02-12

...BRCA2 and PARP as a synthetic lethal target pair to consolidate the use of small molecule inhibitors of RAD51-BRCA2 prot...

Liu(J),Chu(F),Yao(L),Sun(J),Chen(J),Zhang(... Breast Cancer Res Treat 2026-01-06

...BRCA2 PVs, and 10,495 were non-carriers. After a median follow-up of 8.4 years, 10.9% of BRCA1 carriers, 7.2% of BRCA2 c...

Bedell(M),da Silva(EM),Selenica(P),Gazzo(A... J Clin Pathol 2026-04-17

...BRCA2-like/HRD-associated mutational features in addition to shared TP53 alterations. Genomic instability, either due to...